Nacho Aguiló
YOU?
Author Swipe
View article: BCG-induced reprogramming of monocyte/macrophage populations enhances lung antitumor immunity in mice
BCG-induced reprogramming of monocyte/macrophage populations enhances lung antitumor immunity in mice Open
The tumor microenvironment (TME) significantly influences antitumor immunity, with monocytes and macrophages playing pivotal roles both in pro- and anti-tumoral functions. Tumor-associated macrophages (TAMs) often adopt immunosuppressive p…
View article: Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b–2a, double-blind, dose-escalation, randomised controlled trial
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b–2a, double-blind, dose-escalation, randomised controlled trial Open
Congressionally Directed Medical Research Programmes and US National Institutes of Health.
View article: NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice
NK cells mediate preventive efficacy of intravenous BCG against lung metastasis in mice Open
Lung metastases frequently arise from primary tumors, including bladder cancer, and represent a critical negative prognostic factor. Natural Killer (NK) cells have shown to play a vital role in controlling metastasis. Consequently, tumor c…
View article: Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates Open
Introduction Mycobacteria are known to exert a range of heterologous effects on the immune system. The mycobacteria-based Freund’s Complete Adjuvant is a potent non-specific stimulator of the immune response used in immunization protocols …
View article: OA-490 Safety, reactogenicity and immunogenicity of MTBVAC in newborns in a TB endemic area: a phase 2a randomized, double-blind, dose-defining trial
OA-490 Safety, reactogenicity and immunogenicity of MTBVAC in newborns in a TB endemic area: a phase 2a randomized, double-blind, dose-defining trial Open
Background New safe and effective TB vaccine strategies to replace infant BCG vaccination are needed urgently. We evaluated the safety, reactogenicity and immunogenicity of three doses of the live-attenuated Mycobacterium tuberculosis (Mtb…
View article: Cell therapy could benefit from BCG: how anti-tumour BCG-primed NK cells selectively proliferate over other lymphocytes and efficiently kill cancer cells
Cell therapy could benefit from BCG: how anti-tumour BCG-primed NK cells selectively proliferate over other lymphocytes and efficiently kill cancer cells Open
Natural killer (NK) cell-based immunotherapies are safe, promising treatments for patients with cancer. Nevertheless, the short-lived nature of NK cells, the heterogeneity of NK populations and the need to infuse large number of cells for …
View article: BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded <i>in vitro</i>
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded <i>in vitro</i> Open
Bacillus Calmette-Guérin (BCG), the nonpathogenic Mycobacterium bovis strain used as tuberculosis vaccine, has been successfully used as treatment for non-muscle invasive bladder cancer for decades, and suggested to potentiate cellular and…
View article: 1072 Intravenous BCG administration in mice stimulates NK and T cell-mediated antitumor immunity in the lung and overcomes resistance to immunotherapy
1072 Intravenous BCG administration in mice stimulates NK and T cell-mediated antitumor immunity in the lung and overcomes resistance to immunotherapy Open
Background Intravesical administration of the tuberculosis vaccine Bacillus Calmette-Guérin (BCG) was the first immunotherapy to be approved by the FDA and is still nowadays the treatment of choice for a subset of non-muscle invasive bladd…
View article: Systemic BCG administration stimulates NK and T cell-mediated antitumor lung immunity and overcomes tumor resistance to immune checkpoint inhibition
Systemic BCG administration stimulates NK and T cell-mediated antitumor lung immunity and overcomes tumor resistance to immune checkpoint inhibition Open
Intravesical administration of BCG was the first immunotherapy approved by the FDA and it is still nowadays the treatment of choice for a subset of non-muscle invasive bladder cancer patients. Considering this precedent and the strong capa…
View article: Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors Open
Background Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); however, it still fails in a significant proportion of patients, so improved treatment options are urgently needed. Methods Here, we c…
View article: MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG
MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG Open
At its 100th birthday of its first administration to a newborn, BCG has been (and continues being) an inspiration for the construction and development of hundreds of new TB vaccine candidates in the last two and a half decades. Today, 14 c…
View article: Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 Open
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell res…
View article: Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG
Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG Open
Natural Killer cell receptors allow this heterogeneous immune population to efficiently fight both tumors and infection, so their use as immunotherapy agents is an active field of research. Cytokine activation, particularly by myeloid cell…
View article: Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection
Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection Open
To fight tuberculosis, better vaccination strategies are needed. Live attenuated Mycobacterium tuberculosis-derived vaccine, MTBVAC, is a promising candidate in the pipeline, proven to be safe and immunogenic in humans so far. Independent …
View article: Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination
Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination Open
BCG vaccination can strengthen protection against pathogens through the induction of epigenetic and metabolic reprogramming of innate immune cells, a process called trained immunity. We and others recently demonstrated that mucosal or intr…
View article: Independent genomic polymorphisms in the PknH serine threonine kinase locus during evolution of the Mycobacterium tuberculosis Complex affect virulence and host preference
Independent genomic polymorphisms in the PknH serine threonine kinase locus during evolution of the Mycobacterium tuberculosis Complex affect virulence and host preference Open
Species belonging to the Mycobacterium tuberculosis Complex (MTBC) show more than 99% genetic identity but exhibit distinct host preference and virulence. The molecular genetic changes that underly host specificity and infection phenotype …